CTOs on the Move

ALCO Sales and Service Co.

www.alcosales.com

 
However, ALCO can make the following promises and keep them: ALCO promises to earn your trust by providing superior service and products. Good customers deserve the best and we review your orders to assure you get exactly what you ordered. Quality,
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million
  • www.alcosales.com
  • 6851 High Grove Blvd
    Burr Ridge, IL USA 60527
  • Phone: 630.655.1900

Executives

Name Title Contact Details

Similar Companies

American Medical Alert

American Medical Alert Corp. is a Oceanside, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cornerstone Helping Hands

Cornerstone Helping Hands is a Springfield, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Expression Pathology, Inc

Expression Pathology, Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Gaithersburg, MD. To find more information about Expression Pathology, Inc, please visit www.expressionpathology.com

Senomyx

Senomyx is using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients.  These include modifiers of Sweet and Salt flavors as well as Savory Flavors, Bitter Blockers, and Cooling Agents.  The Company is also engaged in an effort to discover and develop natural high-potency sweeteners.  Under its direct sales program, Senomyx is beginning to sell certain of its Complimyx brand flavor ingredients, Sweetmyx, Savorymyx, and Bittermyx, to flavor companies for re-sale to their food and beverage company customers.  In addition, Senomyx has collaborative agreements with global food, beverage, and ingredient supply companies, some of which are currently marketing products that contain Senomyx's flavor ingredients.

Nivalis Therapeutics

Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.